RxDoctor Payments Data

Anthony Nicholas

Neurology · Memphis, TNNPI 1588695928

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. That places this record below the midpoint for neurology clinicians in TN, where the typical reported total is $2,246.

$62in general payments, 2019–2025

Across 2 payments — averaging $31.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tersera Therapeutics LLC$37
  • Amneal Pharmaceuticals LLC$25
$1,777,869in research payments, 2019–2025

Across 85 payments — averaging $20,916 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche TCRC, Inc.$859K
  • Genentech, Inc.$715K
  • Sunovion Pharmaceuticals Inc.$161K
  • AbbVie$42K
  • F. Hoffmann-la Roche AG$711

What the payments were for

  • Food & beverage$62100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$62 in reported general payments places this provider in the 15th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$34,883
Medicare patients
191
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate34$197,747
AustedoDeutetrabenazine14$142,064
NeuproRotigotine35$39,565
GocovriAmantadine Hcl14$27,388
Rasagiline Mesylate79$20,832
Carbidopa-LevodopaCarbidopa/Levodopa284$13,912
Entacapone22$5,849
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone11$5,015
Pramipexole ErPramipexole Di-Hcl12$3,647
Carbidopa-Levodopa ErCarbidopa/Levodopa69$3,565
Primidone102$2,714
Pramipexole DihydrochloridePramipexole Di-Hcl64$1,618
AmantadineAmantadine Hcl21$1,252
Clonazepam206$1,156
Propranolol Hcl ErPropranolol Hcl24$986

Paid to pharmacies, not to this prescriber.

Other neurology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →